SCHEMBL25544237

SCHEMBL25544237

Cc1ccc2c(-c3ccc(F)c(C)c3)c(Cl)nc(Cl)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.36
PTGS1 P23219 3/20 0.36
PTGES O14684 1/20 0.36
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
NTRK1 P04629 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
IGF1R P08069 1/20 0.35
MET P08581 1/20 0.35
PIM1 P11309 1/20 0.35
FGFR1 P11362 1/20 0.35
PRKACA P17612 1/20 0.35
FLT1 P17948 1/20 0.35
LTK P29376 1/20 0.35
GRK5 P34947 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30367989 0.86 ESR1 (0.40) PTGS2PTGS1
SCHEMBL23887779 0.86 ESR1 (0.40) PTGS2PTGS1
SCHEMBL25544512 0.85 GCGR (0.34) PTGS2PTGS1PTGESAURKADAPK3
SCHEMBL30120996 0.84 KDM4E (0.39) PTGS2PTGESAURKARAB9ADHODH
SCHEMBL23887869 0.84 KDM4E (0.39) PTGS2PTGESAURKARAB9ADHODH
SCHEMBL25544569 0.79 PDE2A (0.35) PDE10AMAPK1
SCHEMBL23887781 0.76 ENPP3 (0.41) KDRDYRK1AIKBKEMEN1NPC1
SCHEMBL25544329 0.74 GRM2 (0.36) SRCMEN1KMT2ATRPV3GRM2
SCHEMBL18738221 0.73 ESR1 (0.44) AURKADAPK3JAK2PRKD3MAP4K4
SCHEMBL25544502 0.70 GCGR (0.33) PTGS2AURKADAPK3JAK2PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 PTGS2 1486/4885PTGS1 617/4885PTGES 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.